BIO as Amicus Curiae supporting en banc reconsideration in Prolitec, Inc. v. ScentAir Technologies, Inc. (US Court of Appeals for the Federal Circuit) STATEMENT OF INTEREST OF AMICUS CURIAE The Biotechnology Innovation Organization (“BIO”) (formerly: Biotechnology Industry…
Brief of Amicus Curiae Biotechnology Innovation Organization in Support of Plaintiffs-Appellees in Amgen Inc. v. Apotex Inc. (U.S. Court of Appeals for the Federal Circuit) INTEREST OF AMICUS CURIAE The Biotechnology Innovation Organization (“BIO”) is the world’s largest…
Toolkit | July 30, 2019 | Human Health, Biotech Basics
Private entities take foundational knowledge from public research and invent practical applications that result in real-life treatments and cures for patients.
Philadelphia (July 19, 2018) –The Biotechnology Innovation Organization (BIO) today presented Dr. Larry Walker, co-editor in chief for the journal “Industrial Biotechnology,” with the third annual BIO Leadership and Legacy Award in Industrial Biotechnology and Agriculture. The award…
Toolkit | May 5, 2019 | Intellectual Property, Biotech Basics
In the debate over drug costs, there is a lot of discussion about so-called “evergreening.” The truth is that the U.S. PTO applies the same legal standards to pharmaceutical patents as they do to other technologies.
Toolkit | February 26, 2019 | Human Health, Disease Area
Washington, DC (December 20, 2018) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement applauding passage today by the House of Representatives of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (H.R. 7328)…
The Biotechnology Innovation Organization today released the following statement in response to USDA issuing a final rule implementing the National Bioengineered Food Disclosure Standard: